ELM-1 is an ongoing, open-label, multicenter Phase 1 trial to investigate the safety and tolerability of odronextamab in patients with CD20+ B-cell malignancies previously treated with CD20-directed ...
NEW YORK — “Man, what a crazy game.” Seahawks coach Mike Macdonald’s first press conference words following a 26-21 win over the New York Jets likely encompassed the thoughts of most people who ...